Delivery of single-domain antibodies into neurons using a chimeric toxin–based platform is therapeutic in mouse models of botulism
Year: 2021
Type: article
Source: Science Translational Medicine
Institutions: Boston Children's Hospital, Harvard University, Tufts University
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: National Institutes of Health, Intelligence Advanced Research Projects Activity, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: A platform for therapeutic agents that promote rapid recovery from botulism, Molecular mechanism for retrograde transport of tetanus neurotoxin, New England Regional Center of Excellence in Biodefense and Emerging Infectious D, Structure and Function of C. Difficile Toxins, G740869666, Reversing botulism with agents that accelerate intraneuronal toxin degradation, G7891100991, Molecular basis of action and pathogenesis of Clostridium difficile toxin B, Intellectual and Developmental Disablities Research Center, Integrated Epithelial and Muscosal Biology, Biology and Engineering of Botulinum Neurotoxins., Targeted Delivery of Therapeutics into Motor Neurons for Post-exposure Treatment of Botulism
OpenAlex ID: W3120061304